Brachial Plexus MRI for Tumour

Version 1.0 — August 2026

1. Executive Summary

1.1 Added Value over the Generic Protocol

The generic protocol’s coronal T1/STIR backbone reliably identifies a mass adjacent to or involving the brachial plexus, but full characterisation, staging, and — where relevant — differentiation from post-radiation change requires targeted additions: mandatory post-contrast fat-suppressed T1 sequences, deliberate lesion-morphology assessment (target sign, fusiform vs eccentric growth, multiplicity), and, for apical (Pancoast) tumours specifically, integration with dedicated chest/lung apex imaging that lies outside the generic protocol’s standard coverage. This child page also incorporates post-radiation plexopathy, since its central diagnostic challenge — distinguishing radiation fibrosis from recurrent or new tumour — is inseparable from the tumour-surveillance context in which it typically arises.

1.2 Limits of the Dedicated Protocol

MRI characterises lesion morphology, extent, and enhancement pattern with high sensitivity, but definitive histological diagnosis for an indeterminate nerve sheath lesion still generally requires tissue sampling; imaging findings guide the differential and surgical approach rather than substituting for biopsy in genuinely indeterminate cases. Distinguishing radiation fibrosis from recurrent tumour, while supported by reasonably well-characterised imaging criteria, remains occasionally genuinely indeterminate on a single study, and comparison with a documented post-treatment baseline is the single most valuable diagnostic tool available — one this protocol depends on but cannot create retrospectively if no baseline was obtained.

2. Clinical Context

2.1 Clinical Presentation

Presentation varies with lesion type and location: a slowly enlarging, often painless palpable mass with a positive Tinel sign is typical of a benign nerve sheath tumour (schwannoma, neurofibroma); progressive pain, rapid growth, or new motor deficit raises concern for malignant transformation or a different tumour biology; Pancoast (superior sulcus) tumours classically present with the triad of shoulder/arm pain in a C8-T1 distribution, Horner syndrome (from sympathetic chain involvement), and hand intrinsic muscle wasting; post-radiation plexopathy presents as progressive, painless (in contrast to recurrence, which is more often painful) sensorimotor deficit months to years after radiotherapy.

2.2 Tumour Categories Relevant to the Brachial Plexus

Nerve sheath tumours (schwannoma, neurofibroma, and plexiform neurofibroma in neurofibromatosis type 1) are the most common primary tumours directly involving the plexus. Non-neural masses in the same anatomical region — lipoma and lipofibromatous hamartoma, vascular malformations, and reactive or metastatic lymphadenopathy — enter the differential based on location alone. Pancoast tumour represents direct extrinsic invasion of the lower plexus by an apical lung malignancy rather than a primary nerve tumour, with distinct staging and management implications.

2.3 Differential Diagnosis (Clinical)

A palpable supraclavicular or axillary mass with plexus-distribution symptoms must be distinguished clinically from reactive or malignant lymphadenopathy without direct nerve involvement, from a non-neurogenic soft tissue mass abutting but not infiltrating the plexus, and — in a patient with a treated primary malignancy — from post-radiation or post-surgical fibrosis without recurrence, which is the central diagnostic question this protocol is designed to help resolve.

3. Indications, Timing, and Patient Selection

3.1 When the Dedicated Protocol Is Indicated

Any palpable or incidentally identified mass involving or adjacent to the brachial plexus, known or suspected NF1 with plexiform neurofibroma surveillance, suspected Pancoast tumour, and any new neurological deficit in a patient with a treated regional malignancy (breast, lung, lymphoma) within a plausible radiation field are all indications for this dedicated protocol rather than the generic protocol alone.

3.2 Baseline and Surveillance Imaging

For NF1 plexiform neurofibroma surveillance, and for post-treatment surveillance in patients at risk of post-radiation plexopathy, a documented baseline study — ideally shortly after treatment completion, before any symptoms develop — is of substantial value for future comparison, since the radiation-fibrosis-versus-recurrence distinction (Section 5) depends heavily on demonstrating interval change (or its absence) from a known reference point.

3.3 When Chest/Lung Apex Integration Is Required

Suspected Pancoast tumour requires the generic brachial plexus protocol to be deliberately combined with axial coverage extending into the superior lung and chest wall, since staging depends on assessing invasion of the first rib, subclavian vessels, vertebral bodies, and chest wall in addition to the plexus itself — coverage the standard brachial-plexus-centred field of view does not provide by default.

3.4 Red Flags Modifying Urgency

Rapidly progressive neurological deficit, particularly with new or worsening pain, in a patient with a known nerve sheath tumour (especially NF1) raises concern for malignant peripheral nerve sheath tumour transformation and should prompt more urgent imaging and multidisciplinary review than routine surveillance timing.

4. Dedicated Protocol Design

4.1 Mandatory Core Sequences

The table below lists the complete mandatory protocol for brachial plexus tumour assessment — the five generic-protocol core sequences (1-5) plus the two tumour-specific additions (6-7) detailed in Section 4.3. See Section 4.2 for the full comparison against the generic protocol.

4.2 Protocol Delta vs the Generic Brachial Plexus Protocol

4.3 Mandatory Dedicated Sequences

• Post-contrast T1 fat-suppressed sequences (coronal and axial), per the generic protocol’s conditional listing — mandatory, not optional, whenever a mass, surveillance, or post-radiation indication is the reason for the examination.
• Coronal STIR and T1, per the generic protocol, specifically reviewed for lesion signal characteristics (target sign, fat content, signal homogeneity) rather than only screened for gross abnormality.
• Axial sequences extending to the lung apex/chest wall, specifically for suspected Pancoast tumour, integrating with standard chest MRI technique for full local staging.

4.4 Conditional and Advanced Sequences

• DWI (including high-b DWIBS) may assist in distinguishing tumour from surrounding oedema and in nerve tract visualisation for surgical planning, per the generic protocol’s conditional listing.
• 3D MR neurography sequences improve delineation of the nerve of origin and the relationship of a mass to adjacent, uninvolved nerve fascicles — valuable for surgical planning, particularly for benign nerve sheath tumours where fascicle-sparing resection may be attempted.
• Whole-body or extended-field MRI may be considered for NF1 patients with multiple plexiform neurofibromas, to establish a full-body baseline burden — a decision made in the broader NF1 surveillance context rather than as a routine component of this focused protocol.

4.5 Rationale per Disease-Specific Sequence

Post-contrast T1 fat-suppressed sequences (elevated to mandatory status) The rationale for treating contrast as effectively mandatory here, rather than conditional as in the generic protocol, is that the central diagnostic tasks of this child page — lesion characterisation, perineural tumour spread assessment, and specifically the radiation-fibrosis-versus-recurrence distinction — all depend on enhancement pattern information that non-contrast sequences cannot reliably provide.

Lesion morphology assessment on T2-weighted sequences The rationale for deliberately assessing morphology, not simply detecting a mass, is that specific imaging features carry real differential-diagnostic weight: a target sign (T2-dark centre, T2-bright peripheral rim) favours schwannoma; a fusiform, non-eccentric growth pattern favours neurofibroma; multiplicity and plexiform (worm-like, infiltrative) morphology in a patient with café-au-lait macules strongly suggests NF1-associated plexiform neurofibroma.

Chest/lung apex extension for Pancoast tumour The rationale is that Pancoast tumour staging is fundamentally a question of local invasion extent — first rib, subclavian vessels, vertebral body, chest wall — that cannot be answered by a plexus-only field of view; MRI is specifically valued here because it characterises soft-tissue and neurovascular invasion more reliably than CT for surgical resectability assessment.

Comparison with documented baseline for post-radiation assessment The rationale for building comparison into the protocol design itself, not just the reporting stage, is that radiation fibrosis is classically T2-dark, non-enhancing, and diffuse, while recurrent tumour is classically T2-bright, enhancing, and focal — but these classic patterns are not universal, and demonstrated interval change (or stability) against a genuine prior baseline is frequently the most reliable discriminator in practice.

4.6 Dedicated Planes and Field of View

The generic protocol’s coronal oblique plexus plane remains central for plexus-confined lesions, but must be deliberately extended — axially and, where Pancoast tumour is suspected, superiorly into the chest — well beyond the standard plexus-only field of view whenever the differential includes apical lung malignancy or a mass whose full extent is not confidently contained within the routine coverage.

4.7 Contrast Strategy

Standard macrocyclic GBCA dosing applies, with post-contrast fat-suppressed T1 acquired in both coronal and axial planes. Spectral or Dixon fat suppression is used for the post-contrast series per site-wide policy (STIR being contraindicated post-gadolinium), while pre-contrast fluid-sensitive imaging continues to use STIR as in the generic protocol. For surveillance and post-radiation comparison studies specifically, using an identical or closely matched contrast protocol to the baseline study — same agent class, comparable timing — supports more reliable longitudinal comparison.

4.8 Sequence Matching to Clinical Question

5. MRI Semiotics of Brachial Plexus Tumour

5.1 Direct Signs

Schwannomas classically show a target sign (T2-dark central fibrous/collagenous core, T2-bright peripheral myxoid rim) on high-resolution coronal T2, with avid, often heterogeneous enhancement. Neurofibromas show broadly similar T2 hyperintensity but tend to be fusiform and non-eccentric relative to the parent nerve, in contrast to schwannoma’s typically eccentric relationship. Plexiform neurofibroma, characteristic of NF1, shows a multinodular, “bag of worms” morphology along an extended nerve segment. Perineural tumour spread — whether from a primary nerve sheath tumour or metastatic infiltration — produces T2 signal increase and enhancement tracking longitudinally along the nerve, distinct from a discrete focal mass.

5.2 Indirect and Secondary Signs

Denervation change (STIR-bright, and in chronic cases atrophic, muscle signal) in the distribution of the nerve segment affected by tumour infiltration mirrors the denervation pattern described for traumatic plexopathy, but with a mass or infiltrative signal abnormality as the underlying cause rather than mechanical injury. For Pancoast tumour, secondary signs include first rib destruction, vertebral body invasion, and subclavian vessel encasement or occlusion — findings with direct surgical resectability implications.

5.3 Severity, Extent, and Site Localisation

Reporting should specify the tumour’s relationship to individual plexus elements (which trunk, division, cord, or terminal branch is involved or abutted), its longitudinal extent along the nerve, and — for Pancoast tumour specifically — the specific structures invaded (first rib, subclavian artery/vein, vertebral body, chest wall), since this directly determines surgical resectability staging.

5.4 Relevant Classification Frameworks

Pancoast tumour staging follows standard lung cancer TNM staging, in which brachial plexus and vascular/vertebral invasion are specific T-descriptor determinants; MRI’s role is providing the local soft-tissue and neurovascular invasion detail that directly feeds this staging system, documented practically in oncology/lung cancer staging resources rather than duplicated in full here.

5.5 Differential Diagnosis on Imaging

Key imaging differentials include: schwannoma vs neurofibroma (eccentric/target sign vs fusiform, non-eccentric morphology); benign vs malignant peripheral nerve sheath tumour (rapid growth, ill-defined margins, heterogeneous necrotic-appearing enhancement, and large size favour malignancy, particularly in an NF1 patient); and, centrally to this child page, radiation fibrosis vs recurrent tumour (Section 5.6).

5.6 Mimickers, Pitfalls, and the Radiation Fibrosis vs Recurrence Distinction

The single most clinically important pitfall in this protocol is the radiation-fibrosis-versus-recurrence distinction: radiation fibrosis is classically T2-dark, non-enhancing (or only faintly, diffusely enhancing), and diffuse in distribution, while recurrent tumour is classically T2-bright, avidly and focally enhancing — but early or mixed radiation change can show some T2 hyperintensity and mild enhancement, and this distinction is genuinely important enough to change management that it should never be reported with unwarranted confidence in the absence of a comparison baseline (Section 3.2) or, where genuinely indeterminate, without explicitly recommending short-interval follow-up or biopsy.

6. Reporting Framework

6.1 Structured Reporting Template

Lesion location: nerve/plexus element involved, level. Morphology: target sign / fusiform / plexiform / other, eccentric vs non-eccentric. Signal and enhancement pattern: T2 characteristics, post-contrast enhancement pattern. Extent: longitudinal length along nerve; for Pancoast tumour, specific structures invaded (rib, vessels, vertebral body, chest wall). Comparison with prior imaging: stable / progressed / new, explicitly stated when a baseline exists. Denervation change: present/absent, muscle groups involved.

6.2 Mandatory Reporting Elements

Every report addressing a possible recurrence-versus-fibrosis question should explicitly state whether a prior baseline was available for comparison and, if so, whether the finding represents genuine interval change — an explicit statement of this comparison, not merely a static description of the current study, is required given how central this distinction is to management.

6.3 Critical/Actionable Findings

New or enlarging focal enhancement in a previously irradiated field, any imaging feature suggesting malignant transformation of a known nerve sheath tumour (rapid growth, new pain, ill-defined margins), and evidence of vascular encasement or vertebral body invasion in suspected Pancoast tumour are the most directly actionable findings, each warranting explicit, prominent flagging rather than inclusion within a general descriptive paragraph.

6.4 Common Reporting Errors

Describing a mass without explicit comment on morphology features (target sign, eccentricity, plexiform pattern) that carry real differential-diagnostic weight; failing to explicitly compare against available prior imaging when assessing possible recurrence; and reporting the radiation-fibrosis-versus-recurrence question with more diagnostic certainty than the imaging features actually support.

7. Technical Pitfalls

7.1 Coverage Gaps

Pancoast tumour assessment specifically fails when the field of view remains confined to the standard plexus-only coverage — deliberate, planned extension into the lung apex/chest wall must be requested and set up before the examination begins, not improvised afterward.

7.2 Sequence-Specific Technical Considerations

Distinguishing a target sign or fusiform morphology reliably depends on adequate spatial resolution relative to lesion size; small lesions imaged with the standard, large-FOV generic-protocol resolution may not show these morphology features clearly, and dedicated higher-resolution sequences centred on the lesion itself may be warranted for lesion characterisation once a mass has been identified on the overview sequences.

7.3 When the Generic Protocol Alone Is Insufficient

A brachial plexus MRI performed for known or suspected tumour using only the generic protocol’s conditional contrast approach, without deliberate lesion-morphology assessment and (where relevant) baseline comparison, risks an incomplete characterisation that does not answer the specific clinical questions this indication requires.

8. MRI Technologist Pearls

8.1 Sequence Order Logic

Where a known lesion location is provided in advance (e.g. a palpable mass or a known surveillance target), planning dedicated higher-resolution sequences centred on that specific location, in addition to the standard bilateral overview, improves the likelihood of adequate morphology characterisation without extending overall scan time unnecessarily.

8.2 Positioning Tricks

For suspected Pancoast tumour, coordinate coil selection and positioning to adequately cover both the plexus and the lung apex/chest wall in the same setup where possible, avoiding a need to reposition and re-plan mid-examination.

8.3 Fast Salvage Protocol

If examination time is constrained, prioritise post-contrast fat-suppressed T1 (coronal and axial) above all other sequences in this protocol, since enhancement pattern is the single piece of information most directly tied to this child page’s central diagnostic tasks (lesion characterisation and the fibrosis-versus-recurrence distinction).

8.4 Disease-Specific Common Avoidable Errors

Treating contrast as genuinely optional when the indication is mass characterisation or post-radiation surveillance; failing to extend coverage into the chest for suspected Pancoast tumour; and performing a surveillance or post-treatment study without retrieving and directly comparing against the patient’s prior imaging.

9. Quality Control Checklist

• Post-contrast fat-suppressed T1 confirmed acquired in both coronal and axial planes for any mass, surveillance, or post-radiation indication.
• Coverage confirmed to extend into the lung apex/chest wall whenever Pancoast tumour is a clinical consideration.
• Prior imaging retrieved and available for direct comparison whenever the clinical question involves surveillance or possible recurrence.
• Lesion morphology (target sign, eccentricity, plexiform pattern, multiplicity) explicitly assessed and documented, not only lesion presence/absence.
• Denervation change specifically reviewed in the distribution of any nerve segment involved by tumour.

11. Evidence Gaps and Ongoing Debate

• Radiation fibrosis vs recurrence remains genuinely, sometimes irreducibly, difficult to distinguish on imaging alone. As emphasised in Section 5.6, classic imaging patterns exist but are not universal, and the reviewed literature does not describe a single, fully validated imaging criterion set that reliably resolves this distinction in every case without comparison imaging or, at times, biopsy.
• Malignant transformation criteria for NF1-associated plexiform neurofibroma remain incompletely standardised on MRI alone. While rapid growth, ill-defined margins, and heterogeneous enhancement are recognised suspicious features, a single, fully validated imaging-based malignancy-prediction algorithm distinct from clinical/PET-based assessment is not yet universally established.
• Optimal surveillance interval and technique for post-radiation plexopathy risk remain institution-dependent rather than governed by a single, broadly adopted, evidence-based surveillance schedule specific to brachial plexus imaging.

12. Evidence-Based References

A. Guidelines / Consensus / Society Recommendations

No dedicated society guideline specific to brachial plexus tumour MRI protocol design, distinct from the general ACR Appropriateness Criteria for brachial plexus imaging referenced on the parent master page and standard lung cancer TNM staging resources referenced in Section 5.4, was identified as warranting a separate citation for this child page. Category A is therefore not separately populated here.

B. Systematic Reviews / Meta-analyses

C. Important Prospective / Original Studies

No original prospective study distinct from the comprehensive technical review already cited under Category B was independently verified with a working citation during this research pass. Category C is left unpopulated for this child page rather than citing an unverified source.

D. Technical MRI Papers

Represented by the Szaro et al. 2021 systematic technical review already listed under Category B; a separate, non-duplicative Category D entry is not populated to avoid citing the same source twice.

E. Landmark Historical References

No landmark historical reference specific to brachial plexus tumour imaging, distinct from the modern comprehensive review already cited, was identified as warranting separate citation. Category E is therefore not populated for this child page.

End of document — Brachial Plexus MRI for Tumour — Child Protocol under the MRIninja Neck / Brachial Plexus master page — v1.0 — August 2026 Parent page: Brachial Plexus MRI — Generic Standard Protocol